Majorly, chronic myelogenous leukemia (CML) occurs in adults,
however, it sometimes occurs in children as well. However, targeted
drugs called Tyrosine-Kinase Inhibitors (TKIs) have been effective in
providing long-term survival rates. Meanwhile, the Food and Drug
Administration (FDA) has recently approved dasatinib (Sprycel) for
the treatment of chronic myelogenous leukemia in children. As the
chronic myeloid leukemia is more aggressive in younger patients, the
approval of drugs can help in effective treatment.
Request for Sample Copy of Report @
https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=34940
Some of the factors such as a rise in research and development in
oncology sector, innovation in drug development, new products in the
pipeline, and the establishment of novel therapies are resulting in
the growth of the global chronic myelogenous leukemia market.
However, the high cost of treatment is one of the biggest factor
hampering the growth of the global chronic myelogenous leukemia
market.
Some of the key players included in the report are Novartis, Bristol
Myers Squibb, Pfizer, Hoffman-LaRoche and Schering Plough, Teva
Pharmaceutical, and Others. The key players are entering into the
mergers and acquisitions, partnerships, for new product launches and
to expand geographically.
As per the latest report by Transparency Market Research (TMR), the
global chronic myelogenous leukemia market is expected to witness
strong growth. The market is estimated to register 6.7% CAGR during
the forecast period 2017-2026. It is also expected to reach US$
8,550.8 million revenue by the end of 2026.
Enquiry for discount on this report @
https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=34940
The global chronic myelogenous leukemia market is segmented on the
basis of drug type, treatment type, distribution channel, and region.
Based on the drug type, the market segment includes generic and
branded drug. Among these, Branded drugs are expected to account for
highest revenue share. On the basis of treatment type, the segment
includes symptomatic treatment and disease specific treatment. During
the forecast period 2017-2026, disease specific treatment is expected
to witness significant growth.
Based on the distribution channel, the market is categorized into
specialty pharmacies, hospital pharmacies, and retail pharmacies.
Hospital pharmacies are expected to be the largest distribution
channel during the forecast period 2017-2026. Region-wise, the
segmentation includes North America, Latin America, Europe, Japan,
Asia Pacific Excluding Japan (APEJ), and the Middle East and Africa
(MEA). North America is expected to remain dominant in the global
chronic myelogenous leukemia market through 2026.
Chronic myelogenous leukemia is a type of blood cancer that cannot be
cured with normal treatments. Hence, a new class of drugs known as
Tyrosine-Kinase Inhibitors (TKIs) has been developed that is
resulting in the more effective treatment of CML. These class of
drugs is also known as BCR-ABL inhibitors. Imatinib, which is known
as first generation TKI, is quickly becoming a standard treatment for
chronic myelogenous leukemia. Meanwhile, Nilotinib is a second
generation TKI which is being used by patients who are no longer able
to respond to imatinib. TKIs are expensive, hence, generic imatinibs
have also been introduced in various countries. The biggest
restricting factor in the use of TKIs is the high cost of these
drugs. TKIs, including imatinib drug, is effective at killing
leukemic cells, but still is not able to kill the CML cells from
which the disease is born. Hence, new research is also being carried
out for more advanced and effective treatment.
Report Overview @
https://www.transparencymarketresearch.com/chronic-myelogenous-leukemia-treatment-market.html
About Us
Transparency Market Research (TMR) is a market intelligence company,
providing global business information reports and services. Our
exclusive blend of quantitative forecasting and trends analysis
provides forward-looking insight for thousands of decision makers.
TMR’s experienced team of analysts, researchers, and consultants,
use proprietary data sources and various tools and techniques to
gather, and analyze information. Our business offerings represent the
latest and the most reliable information indispensable for businesses
to sustain a competitive edge.
Each TMR syndicated research report covers a different sector - such
as pharmaceuticals, chemicals, energy, food & beverages,
semiconductors, med-devices, consumer goods and technology. These
reports provide in-depth analysis and deep segmentation to possible
micro levels. With wider scope and stratified research methodology,
TMR’s syndicated reports strive to provide clients to serve their
overall research requirement.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website:
https://www.transparencymarketresearch.com
No comments:
Post a Comment